Cargando…

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Dorrer, H, Ghezzi, C, Haddad, F, Jensen, M, Köster, U, Müller, C, Pichler, B, Rolle, AM, Schibli, R, Siikanen, J, Türler, A, Wiehr, S, Zhernosekov, K
Publicado:	2011
Materias:	Detectors and Experimental Techniques
Acceso en línea:	http://cds.cern.ch/record/1387984

Ejemplares similares

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Airaksinen, A, et al.
Publicado: (2016)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Köster, Ulli
Publicado: (2017)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Production and separation of (43)Sc for radiopharmaceutical purposes
por: Domnanich, Katharina A., et al.
Publicado: (2017)

Innovative radioisotopes for preclinical and clinical studies in nuclear medicine
por: Assmann Walter, LMU Munich, et al.
Publicado: (2010)

Radiopharmaceuticals and other compounds labelled with short-lived radionuclides
por: Welch, Michael J
Publicado: (2013)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

(188)Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy
por: Boschi, Alessandra, et al.
Publicado: (2017)

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges
por: Salih, Suliman, et al.
Publicado: (2022)

Prospects in Folate Receptor-Targeted Radionuclide Therapy
por: Müller, Cristina, et al.
Publicado: (2013)

Production of innovative radionuclides for therapy and diagnostics: nuclear data measurements and comparisons with TALYS code
por: Guertin, A, et al.
Publicado: (2019)

Innovative radiopharmaceuticals in oncology and neurology
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2017)

An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals
por: Vichi, Sara, et al.
Publicado: (2016)

Development and optimization of targeted radionuclide tumor therapy using folate based radiopharmaceuticals
por: Reber, Josefine Astrid
Publicado: (2015)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
por: Barbet, Jacques, et al.
Publicado: (2017)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
por: Li, Wei Bo, et al.
Publicado: (2022)

Tumor Immunotargeting Using Innovative Radionuclides
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α(v)β(3)-Targeted Radionuclide Therapy
por: Yang, Guangjie, et al.
Publicado: (2022)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)

Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA
por: Pereira, Edgar, et al.
Publicado: (2017)

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
por: Müller, Cristina, et al.
Publicado: (2016)

Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates
por: Busslinger, Sarah D., et al.
Publicado: (2023)

Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals
por: Zhou, Xu, et al.
Publicado: (2021)

Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility
por: Bernerd, C, et al.
Publicado: (2023)

Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2
por: Pallares, Roger M., et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice
por: Pellegrini, Giovanni, et al.
Publicado: (2017)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

Dosing Therapeutic Radiopharmaceuticals in Obese Patients
por: van Nuland, Merel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kaq99o8vvahtg6fl51ki8uda3l